Angelini Pharma Buys Catalyst Pharma for $4.1 Billion
The Italian drugmaker Angelini Pharma has agreed to acquire Florida-based Catalyst Pharmaceuticals for $31.50 per share in cash. This deal marks Angelini's entry into the United States market and focuses on expanding its global presence in neurological rare disease treatments.
Xurve View
Insights:
Xurve View
Angelini Pharma will acquire Catalyst Pharmaceuticals for $4.1 billion to enter the United States market. The $31.50 per share cash offer represents a 3% premium over the last closing price. The deal establishes the Italy-based drugmaker as a global competitor in neurological rare disease treatments.
Blackstone funds and select international partners will support the acquisition. BNP Paribas is serving as the global coordinator and underwriter for the transaction.
